Natco Pharma Invests USD 8 Million in eGenesis for Groundbreaking Xenotransplantation Research!

Natco Pharma Ltd has announced a USD 8 million (approximately Rs 70 crore) investment in U.S.-based biotechnology company eGenesis, Inc. through its Canadian subsidiary, Natco Pharma (Canada) Inc. This strategic investment underscores Natco’s commitment to advancing the field of xenotransplantation, an innovative area of biotechnology aimed at developing human-compatible organs for transplant.

eGenesis, Inc., a leader in xenotransplantation, focuses on addressing the global organ shortage and providing new treatment options for patients suffering from organ failure. The company’s recent achievements include a successful porcine kidney transplant in a living patient in March 2024, a procedure authorized by the U.S. Food & Drug Administration (USFDA).

Rajeev Nannapaneni, Vice Chairman and CEO of Natco Pharma, emphasized the potential impact of xenotransplantation, stating that the technology could drastically reduce waitlist mortality and revolutionize the field of organ transplantation. Xenotransplantation involves using organs, tissues, or cells from non-human sources to treat human medical conditions, providing a potential solution to the global organ shortage.

eGenesis CEO Mike Curtis welcomed Natco’s support, noting that the investment will further their research and bring cutting-edge xenotransplantation therapies to market.

Established in 1981, Natco Pharma is a globally recognized Indian pharmaceutical company with a focus on producing generic and specialty medicines, particularly in the areas of oncology, cardiology, and hepatology. With operations in India, the United States, and other international markets, Natco is known for launching complex generic drugs and investing heavily in research and development to improve healthcare access globally.